Packaged-food giant ConAgra is planning to label some of its Healthy Choice frozen meals "GLP-1 friendly" in an effort to respond to the effect that the obesity drugs, made by Novo Nordisk, Eli Lilly ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Alphabet could benefit from the growth of AI and cloud computing for years, especially considering the company's competitive ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Tesla CEO Elon Musk calls for making weight loss drugs super low cost to improve American health, aligning with healthcare ...